{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:10:53Z","timestamp":1788963053955,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T00:00:00Z","timestamp":1788912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100018736","name":"Kaken Pharmaceutical","doi-asserted-by":"publisher","award":["JP23K14409"],"award-info":[{"award-number":["JP23K14409"]}],"id":[{"id":"10.13039\/100018736","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"DOI":"10.1007\/s13318-026-01035-9","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:26:07Z","timestamp":1788960367000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetic Analysis of Everolimus Based on Albumin\u2013Bilirubin Scores in Kidney Transplant Recipients"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3898-2068","authenticated-orcid":false,"given":"Toshinori","family":"Hirai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiko","family":"Aoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiharu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chihiro","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kouhei","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Iwamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,9]]},"reference":[{"key":"1035_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.cell.2006.01.016","volume":"124","author":"S Wullschleger","year":"2006","unstructured":"Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell. 2006;124:471\u201384.","journal-title":"Cell"},{"key":"1035_CR2","doi-asserted-by":"publisher","first-page":"547","DOI":"10.2165\/00003495-200666040-00009","volume":"66","author":"C Dunn","year":"2006","unstructured":"Dunn C, Croom KF. Everolimus: a review of its use in renal and cardiac transplantation. Drugs. 2006;66:547\u201370.","journal-title":"Drugs"},{"key":"1035_CR3","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/j.1432-2277.2012.01465.x","volume":"25","author":"RM Langer","year":"2012","unstructured":"Langer RM, Hen\u00e9 R, Vitko S, Christiaans M, Tedesco-Silva H Jr., Ciechanowski K, et al. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation. Transpl Int. 2012;25:592\u2013602.","journal-title":"Transpl Int"},{"key":"1035_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S0140-6736(10)62318-5","volume":"377","author":"K Budde","year":"2011","unstructured":"Budde K, Becker T, Arns W, Sommerer C, Reinke P, Eisenberger U, et al. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet. 2011;377:837\u201347.","journal-title":"Lancet"},{"key":"1035_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/TP.0b013e3181de1d67","volume":"90","author":"L Chan","year":"2010","unstructured":"Chan L, Hartmann E, Cibrik D, Cooper M, Shaw LM. Optimal everolimus concentration is associated with risk reduction for acute rejection in de novo renal transplant recipients. Transplantation. 2010;90:31\u20137.","journal-title":"Transplantation"},{"key":"1035_CR6","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/j.1600-6143.2012.04334.x","volume":"13","author":"AC Wiseman","year":"2013","unstructured":"Wiseman AC, McCague K, Kim Y, Geissler F, Cooper M. The effect of everolimus versus mycophenolate upon proteinuria following kidney transplant and relationship to graft outcomes. Am J Transplant. 2013;13:442\u20139.","journal-title":"Am J Transplant"},{"key":"1035_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1111\/ctr.12045","volume":"27","author":"FS Shihab","year":"2013","unstructured":"Shihab FS, Cibrik D, Chan L, Kim YS, Carmellini M, Walker R, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving reduced cyclosporine. Clin Transplant. 2013;27:217\u201326.","journal-title":"Clin Transplant"},{"key":"1035_CR8","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/FTD.0000000000000260","volume":"38","author":"M Shipkova","year":"2016","unstructured":"Shipkova M, Hesselink DA, Holt DW, Billaud EM, van Gelder T, Kunicki PK, et al. Therapeutic drug monitoring of everolimus: a consensus report. Ther Drug Monit. 2016;38:143\u201369.","journal-title":"Ther Drug Monit"},{"key":"1035_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/bcp.12182","volume":"77","author":"A Albarmawi","year":"2014","unstructured":"Albarmawi A, Czock D, Gauss A, Ehehalt R, Lorenzo Bermejo J, Burhenne J, et al. CYP3A activity in severe liver cirrhosis correlates with Child\u2013Pugh and model for end-stage liver disease (MELD) scores. Br J Clin Pharmacol. 2014;77:160\u20139.","journal-title":"Br J Clin Pharmacol"},{"key":"1035_CR10","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1200\/JCO.2014.57.9151","volume":"33","author":"PJ Johnson","year":"2015","unstructured":"Johnson PJ, Berhane S, Kagebayashi C, Satomura S, Teng M, Reeves HL, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33:550\u20138.","journal-title":"J Clin Oncol"},{"key":"1035_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/1471-230X-12-2","volume":"12","author":"Y Sumida","year":"2012","unstructured":"Sumida Y, Yoneda M, Hyogo H, Itoh Y, Ono M, Fujii H, et al. Validation of the FIB4 index in a Japanese nonalcoholic fatty liver disease population. BMC Gastroenterol. 2012;12:2.","journal-title":"BMC Gastroenterol"},{"key":"1035_CR12","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1035_CR13","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2165\/11599710-000000000-00000","volume":"51","author":"DJ Moes","year":"2012","unstructured":"Moes DJ, Press RR, den Hartigh J, van der Straaten T, de Fijter JW, Guchelaar HJ. Population pharmacokinetics and pharmacogenetics of everolimus in renal transplant patients. Clin Pharmacokinet. 2012;51:467\u201380.","journal-title":"Clin Pharmacokinet"},{"key":"1035_CR14","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1248\/bpb.b21-00778","volume":"45","author":"T Aoyama","year":"2022","unstructured":"Aoyama T, Hirai T, Tsuji Y, Miyamoto A, Itoh T, Iwamoto T, et al. External evaluation of a Bayesian warfarin dose optimization based on a kinetic-pharmacodynamic model. Biol Pharm Bull. 2022;45:136\u201342.","journal-title":"Biol Pharm Bull"},{"key":"1035_CR15","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/cpt.2897","volume":"113","author":"AC Ozbey","year":"2023","unstructured":"Ozbey AC, Bachmann F, Duthaler U, Annaert P, Fowler S, Umehara K, et al. Dose adjustment in patients with liver cirrhosis - comparison of two different modeling approaches. Clin Pharmacol Ther. 2023;113:1346\u201358.","journal-title":"Clin Pharmacol Ther"},{"key":"1035_CR16","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2165\/00003088-200443020-00002","volume":"43","author":"GI Kirchner","year":"2004","unstructured":"Kirchner GI, Meier-Wiedenbach I, Manns MP. Clinical pharmacokinetics of everolimus. Clin Pharmacokinet. 2004;43:83\u201395.","journal-title":"Clin Pharmacokinet"},{"key":"1035_CR17","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1002\/bjs.1800600817","volume":"60","author":"RN Pugh","year":"1973","unstructured":"Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 1973;60:646\u20139.","journal-title":"Br J Surg"},{"key":"1035_CR18","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1053\/jhep.2001.22172","volume":"33","author":"PS Kamath","year":"2001","unstructured":"Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33:464\u201370.","journal-title":"Hepatology"},{"key":"1035_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100557","volume":"4","author":"H Toyoda","year":"2022","unstructured":"Toyoda H, Johnson PJ. The ALBI score: from liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4:100557.","journal-title":"JHEP Rep"},{"key":"1035_CR20","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.clinthera.2013.02.007","volume":"35","author":"J Peveling-Oberhag","year":"2013","unstructured":"Peveling-Oberhag J, Zeuzem S, Yong WP, Kunz T, Paquet T, Bouillaud E, et al. Effects of hepatic impairment on the pharmacokinetics of everolimus: a single-dose, open-label, parallel-group study. Clin Ther. 2013;35:215\u201325.","journal-title":"Clin Ther"},{"key":"1035_CR21","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/15360288.2020.1785070","volume":"34","author":"H Kokubun","year":"2020","unstructured":"Kokubun H, Takigawa C, Chihara S, Hara S, Uezono Y. Population pharmacokinetics of methadone after oral administration in Japanese patients with cancer-related pain. J Pain Palliat Care Pharmacother. 2020;34:203\u201310.","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"1035_CR22","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1248\/bpb.b20-00084","volume":"43","author":"M Homma","year":"2020","unstructured":"Homma M, Kokubun H, Okuwaki K, Katada C, Hayashi N, Kanai A, et al. Pharmacokinetic analysis, analgesic effects, and adverse effects of tapentadol in cancer patients with pain. Biol Pharm Bull. 2020;43:1000\u20136.","journal-title":"Biol Pharm Bull"},{"key":"1035_CR23","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s40262-018-0646-5","volume":"57","author":"I Robertsen","year":"2018","unstructured":"Robertsen I, Debord J, \u00c5sberg A, Marquet P, Woillard JB. A limited sampling strategy to estimate exposure of everolimus in whole blood and peripheral blood mononuclear cells in renal transplant recipients using population pharmacokinetic modeling and Bayesian estimators. Clin Pharmacokinet. 2018;57:1459\u201369.","journal-title":"Clin Pharmacokinet"},{"key":"1035_CR24","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1097\/TP.0b013e31820ae4ac","volume":"91","author":"N Picard","year":"2011","unstructured":"Picard N, Rouguieg-Malki K, Kamar N, Rostaing L, Marquet P. CYP3A5 genotype does not influence everolimus in vitro metabolism and clinical pharmacokinetics in renal transplant recipients. Transplantation. 2011;91:652\u20136.","journal-title":"Transplantation"},{"key":"1035_CR25","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1111\/ajt.14215","volume":"17","author":"F Shihab","year":"2017","unstructured":"Shihab F, Qazi Y, Mulgaonkar S, McCague K, Patel D, Peddi VR, et al. Association of clinical events with everolimus exposure in kidney transplant patients receiving low doses of tacrolimus. Am J Transplant. 2017;17:2363\u201371.","journal-title":"Am J Transplant"},{"key":"1035_CR26","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1592\/phco.22.3.154.33542","volume":"22","author":"JM Kovarik","year":"2002","unstructured":"Kovarik JM, Hartmann S, Figueiredo J, Rordorf C, Golor G, Lison A, et al. Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants. Pharmacotherapy. 2002;22:154\u20139.","journal-title":"Pharmacotherapy"},{"key":"1035_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1097\/FTD.0000000000000474","volume":"40","author":"AG Verstraete","year":"2018","unstructured":"Verstraete AG, Rigo-Bonnin R, Wallemacq P, Vogeser M, Schuetzenmeister A, Schmiedel C, et al. Multicenter evaluation of a new electrochemiluminescence immunoassay for everolimus concentrations in whole blood. Ther Drug Monit. 2018;40:59\u201368.","journal-title":"Ther Drug Monit"},{"key":"1035_CR28","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s10928-005-0083-6","volume":"32","author":"JE Ahn","year":"2005","unstructured":"Ahn JE, Birnbaum AK, Brundage RC. Inherent correlation between dose and clearance in therapeutic drug monitoring settings: possible misinterpretation in population pharmacokinetic analyses. J Pharmacokinet Pharmacodyn. 2005;32:703\u201318.","journal-title":"J Pharmacokinet Pharmacodyn"}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-026-01035-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-026-01035-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:26:08Z","timestamp":1788960368000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-026-01035-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":28,"alternative-id":["1035"],"URL":"https:\/\/doi.org\/10.1007\/s13318-026-01035-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,9]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Clinical Research Ethics Review Committee at each institution (Mie University Hospital: H2022-171; Nihon University: 22A-009-1).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}}]}}